6/26/2025

AtriCure has continued to post losses, even though relative losses are coming down. Find out why ATRC stock is a Hold.

Source: SeekingAlpha

6/12/2025

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

Source: Yahoo

6/9/2025

Presenter SpeechUnknown Analyst We'll go ahead and get started here. I think it is one of the final presentations today. It's nice to be in a room with a window. So, I think that is a bonus. So, I...

Source: Finnhub

5/27/2025

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

Source: Yahoo

5/23/2025

MASON, Ohio, May 23, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference.

Source: Yahoo

5/15/2025

The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Source: Yahoo

5/9/2025

Although many equity markets slipped in January, they recovered over the next two months for a strong first quarter of 2024.

Source: SeekingAlpha

5/2/2025

Creating a World Class Platform Investor Presentation April 2025 © 2025 AtriCure, Inc. All rights reserved. ...

Source: Finnhub

5/1/2025

Apr. 29, 2025-- AtriCure, Inc. , a leading innovator in surgical treatments and therapies for atrial fibrilla...

Source: Finnhub

5/1/2025

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Source: Yahoo

4/30/2025

Q1 2025 AtriCure Inc Earnings Call

Source: Yahoo

4/30/2025

AtriCure Inc (ATRC) reports a 14% revenue increase and significant EBITDA improvement, driven by robust performance in pain and appendage management segments.

Source: Yahoo

4/29/2025

AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ETCompany ParticipantsMarissa Bych - Investor Relations, Gilmartin...

Source: SeekingAlpha

4/29/2025

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Source: Yahoo

4/29/2025

AtriCure (ATRC) delivered earnings and revenue surprises of 44% and 0.16%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

4/29/2025

MASON, Ohio (AP) — AtriCure Inc. (ATRC) on Tuesday reported a loss of $6.7 million in its first quarter. On a per-share basis, the Mason, Ohio-based company said it had a loss of 14 cents. The results beat Wall Street expectations.

Source: Yahoo

4/29/2025

MASON, Ohio, April 29, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results.

Source: Yahoo

4/29/2025

Presentation Operator MessageOperator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions]

Source: Finnhub

4/10/2025

LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Source: Yahoo

4/10/2025

MASON, Ohio, April 10, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ® device for minimally invasive concomitant procedures, the AtriClip PRO-Mini® LAA Exclusion System. The AtriClip PRO-Mini device received FDA 510K clearance earlier this year and is a testament to AtriCure’s commitment to

Source: Yahoo